Skip to main content

Table 4 Clinical symptoms observed among SCD patients with the FVL G1691A and prothrombin G20210A mutations versus SCD patients without these mutations. Results are expressed as frequency and percentages

From: Factor V Leiden G1691A and prothrombin G20210A mutations among Palestinian patients with sickle cell disease

  FVL mutant (N = 20) FVL wild (N = 97) P-value Prothrombin mutant (N = 8) Prothrombin wild (N = 109) P value
Joints pain 16 (80%) 41 (42.2%) 0.0132 4 (50%) 55 (50.4%) NSa
Chest pain 18 (90%) 52 (53.6%) 0.006 4 (50%) 57 (52.2%) NS
Abdominal pain 14 (70%) 48 (49.5%) 0.0311 4 (50%) 61 (55.9%) NS
Splenomegaly 18 (90%) 53 (54.6%) 0.0071 3 (37.5%) 49 (44.9%) NS
Frequency of Blood transfusion (no./year)
0–2 2 (10%) 21 (21.6%) NS 1 (12.5%) 29 (26.6%) NS
3–5 3 (15%) 7 (7.2%) 0.047 2 (25%) 45 (41.3%) NS
6–9 11 (55%) 4 (4.1%) 0.018 4 (50%) 23 (21.1%) 0.003
≥ 10 1 (5%) 0 (0%) NS ------- ------- -------
  1. aNS not significant